TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed patients with overt multiple myeloma who are not candidates for HDT/SCT because of old age (\> 65) or presence of comorbid conditions likely to have a negative impact on tolerability of HDT/SCT. Sponsors review this conditions and approval is required.~* Presence of measurable disease : serum M-protein \> 1g/dL or urine M- protein \> 400mg/day~* Performance status £ ECOG 2~* Expected survival ³ 6 months~* Pretreatment clinical laboratory values meeting the following criteria within 14 days before enrollment platelet ≥ 100 x 109/L hemoglobin ≥ 8 g/dL (≥ 4.96 mol/L) Prior RBC transfusion or recombinant human erythropoietin use is allowed) absolute neutrophil count (ANC) ≥ 1.0 x 109/L aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal total bilirubin ≤ 1.5 times the upper limit of normal serum creatinine ≤ 3mg/dL corrected serum calcium \<14 mg/dL (\<3.5 mmol/L)~* Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.~Exclusion Criteria:~* Smoldering or indolent myeloma~* History of allergic reaction attributable to compounds containing boron or mannitol~* Known hypersensitivity to thalidomide or dexamethasone~* Peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by NCI CTCAE version 3~* Uncontrolled or severe cardiovascular disease, including MI within 6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis, cardiac ejection fraction \<0.5 : Severe conduction disorder : Hypotension (sitting systolic BP ≤ 100 mmHg and/or sitting diastolic BP ≤ 60 mmHg~* Sepsis~* Pregnancy or breastfeeding~* Uncontrolled Diabetes Mellitus~* Recurrent DVT or pulmonary embolism~* Active ulcers detected by gastroscopy~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.~* Receipt of extensive radiation therapy within 4 weeks

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Needle Guidance in Ultrasound Guided Nerve Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women 18-85 years old~* Scheduled for elective knee surgery and expected to receive a femoral nerve block and catheter~* Written informed consent~Exclusion Criteria:~* Contraindications to femoral block such as coagulopathy, infection at the needle insertion site and allergy to local anesthetics~* Pregnancy~* Preexisting neuropathy involving the surgical limb

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Infiniti Plus needle guidance system (Type: EXPERIMENTAL): ultrasound guidance with the InfinitiPlus (TM) needle guidance system
- conventional block needle (Type: OTHER): ultrasound guidance with a conventional block needle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of epilepsy with simple partial seizures and/or complex partial seizures~* Stable dose regimen of 1 to 2 marketed antiepileptic drug(s) (AED(s)) for 28 days prior to screening and duration of trial~* Acceptable candidate for venipuncture and intravenous (iv) infusion~* At least 1 partial seizure with motor component per 90 days~* Maximum allowed seizure frequency during 28 days prior to screening is 40 partial seizures of any type~Exclusion Criteria:~* Previous use of lacosamide~* History of primary generalized seizures~* History of status epilepticus within last 12 months~* History of cluster seizures during 8 week period prior to screening~* Non-epileptic events, including psychogenic seizures that could be confused with seizures~* Use of neuroleptics, monoamine oxidase (MAO) inhibitors, barbiturates, or narcotic analgesics within 28 days prior to screening~* Received any rescue benzodiazepines more than once during the 28 days prior to screening~* Concomitant treatment of felbamate or previous felbamate therapy within last 6 months~* Prior or concomitant vigabatrin use

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide 200 mg cohort (Type: EXPERIMENTAL): Single loading dose of intravenous (iv) lacosamide 200 mg followed by 6.5 days of oral lacosamide 100 mg twice daily
- Lacosamide 300 mg combined cohorts (Type: EXPERIMENTAL): Single loading dose of intravenous (iv) lacosamide 300 mg dose followed by 6.5 days of oral lacosamide 150 mg twice daily
- Lacosamide 400 mg cohort (Type: EXPERIMENTAL): Single loading dose of intravenous (iv) lacosamide 400 mg followed by 6.5 days of oral lacosamide 200 mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between, and including, the ages of 40 and 80 years.~* Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage II-III disease, subjects must have had stable disease for at least 1 month prior to screening.~* Subjects must have a smoking history of at least 10 pack-years and be current smokers or ex-smokers that gave up \> 6 months ago.~Exclusion Criteria:~* More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalization for the treatment of COPD within 3 months of screening or more than twice during the preceding year.~* History or presence of significant cardiovascular disease.~* ECG abnormalities.~* Significant concomitant clinical disease that could interfere with the conduct, safety or interpretation of results of this study.~* Evidence of organ or blood disorders.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PH-797804 (Type: EXPERIMENTAL): PH-797804 at four dose levels
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stage 1,2,3 breast cancer~* Her2+~Exclusion Criteria:~* Stage 4 cancer

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CC resistant PCOS~* Infertile~* Females~* Age 18-38~Exclusion Criteria:~* Hyperprolactinaemia~* Cushing syndrome~* Adult onset adrenal hyperplasia~* Age \>38~* Other infertility factors in the couple than PCOS: male factor,tubal factor,edometriosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Clomiphene Citrate plus HP uFSH (Type: EXPERIMENTAL): Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
- Step-up HP uFSH (Type: ACTIVE_COMPARATOR): HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Haemocomplettan® P During Aortic Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eighteen years of age or older~* Undergoing elective thoracoabdominal aortic replacement surgery (TAAA) or thoracic aortic replacement surgery (TAA)~* Understood and willingly given written informed consent (German language) to participate following an explanation of study background, restrictions, and procedures~* Experience clinically relevant bleeding of the microvasculature following removal of CPB during surgery~Exclusion Criteria:~* Positive pregnancy test, pregnancy or lactation~* Women of child bearing age not using a medically approved method of contraception during the study~* Previous aortic replacement at the same aortic site (redo surgeries)~* Undergoing an emergency operation~* Proof or suspicion of a congenital or acquired coagulation disorder (e.g. VWD or via severe liver disease)~* Myocardial Infarction (MI) or apoplexy in the 2 months preceding study surgery~* ASA administration in the 3 days preceding study surgery, and a pathological (\<74.5 U) ASPI Multiplate® test immediately preceding surgery begin~* Clopidogrel administration in the 5 days preceding study surgery, and a pathological (\<31.1 U) ADP/PG Multiplate® test immediately preceding surgery begin~* Tirofiban administration in the 2 days preceding study surgery, and a pathological (\<94.1 U) TRAP Multiplate® test immediately preceding surgery begin~* Phenprocoumon administration in the 5 days preceding study surgery, and an INR \> 1.28 immediately preceding surgery begin~* Participation in another clinical study in the 4 weeks preceding aortic replacement~* Sensitivity to any of the components of study medication, or to MPs with a similar chemical structure to any of the components of study medication~* Any indication that the restrictions or procedures of the study may not be adhered to (e.g. an uncooperative attitude)~* Any indication that the study restrictions, procedures, or consequences therein have not been considered or understood, such that informed consent cannot be convincingly given~* Multiple morbidities, with a notably constrained remaining length of life

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Haemocomplettan® P (Type: ACTIVE_COMPARATOR): Intravenous infusion during aortic surgery
- Saline solution (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed post-transplant lymphoproliferative disease (PTLD)~  * Presents with 1 of the following:~    * Fulminant PTLD (F-PTLD)~      * Fever greater than 38°C~     * Hypotensive (for age)~     * Evidence of multiple organ involvement/failure, including at least 2 of the following:~        * Marrow (including pancytopenia without detectable B-cell proliferation)~       * Liver (coagulopathy, transaminitis, and/or hyperbilirubinemia)~       * Lungs (interstitial pneumonitis with or without pleural effusions)~       * Gastrointestinal tract hemorrhage~   * Non-fulminant PTLD (NF-PTLD)~      * Does not meet the above F-PTLD criteria~     * Considered medically refractory to reduced immune suppression (50% or more reduction of immunosuppression) for at least 1 week~* CD20 positive AND Epstein-Barr virus positive~* Must have received prior solid organ transplantation~* Must have residual disease after biopsy and/or surgery~* No PTLD central nervous system (CNS) disease, defined as positive cytology and/or radiographic evidence~PATIENT CHARACTERISTICS:~Age~* Under 31~Performance status~* Not specified~Life expectancy~* NF-PTLD patients:~  * At least 8 weeks~Hematopoietic~* See Disease Characteristics~Hepatic~* See Disease Characteristics~Renal~* Not specified~Pulmonary~* See Disease Characteristics~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 1 month since prior rituximab~Chemotherapy~* More than 4 weeks since prior chemotherapy and recovered~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide, prednisone, rituximab (Type: EXPERIMENTAL): Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5. During courses 1 and 2 only, patients also receive rituximab IV over 2-5 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression, a new primary or secondary malignancy, or unrelated disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Visual Analogue Scale (VAS) of pain is higher than 40 mm.~* Pain is sustained for more than 3 months after healing of herpes zoster skin rash.~Exclusion Criteria:~* Malignancy within the past 2 years.~* Patients who have undergone neurolytic or neurosurgical therapy for postherpetic neuralgia.~* Creatinine clearance \</= 30 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).~* Patients having other severe pain which may impair the self assessment of the pain due to postherpetic neuralgia.~* Skin conditions in the affected dermatome that could alter sensation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pregabalin 150mg/day (Type: EXPERIMENTAL): None
- Pregabalin 300mg/day (Type: EXPERIMENTAL): None
- Pregabalin 600mg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of a Wearable-enabled Intervention for Promoting Physical Activity in People Knee OA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a physician confirmed diagnosis of knee osteoarthritis OR are both 1) over 50, and 2) have experienced 4 weeks of pain, aching, or discomfort in or around the knee during the last year (equal to or more than 28 separate or consecutive days).~* Have no previous diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, connective tissue diseases, fibromyalgia or gout.~* Have no history of using disease-modifying anti-rheumatic drugs or gout medications.~* Have no prior knee replacement surgery, and not on a waiting list for total knee replacement surgery.~* Have no history of acute injury to the knee in the past 6 months.~* Have not had surgery in the back, hip, knee, foot or ankle joints in the past 12 months.~* Have an email address and daily access to a computer with internet connection.~* Be able to attend a 2-hour education session at the Mary Pack Arthritis Centre.~Exclusion Criteria:~* Have a body mass index of equal to or greater than 40~* Have received a steroid injection in a knee in the last 6 months~* Have received a hyaluronate injection in a knee in the last 6 months~* Use medication that may impair activity tolerance (e.g. beta blockers)~* Are at risk when exercising, as identified by the Physical Activity Readiness Questionnaire (PAR-Q)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Intervention Group (Type: ACTIVE_COMPARATOR): Education session, Fitbit Flex, and remote coaching by a PT. These three components of the intervention will be delivered to the participants in Month 1. At the end of the education session, the PT will help participants set personal activity goals. In Month 1, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute weekly phone calls and progressively modify their activities. In Month 2, they will continue using the Fitbit and have access to a PT via email as needed, but no weekly phone calls.
- Delayed Intervention Group (Type: PLACEBO_COMPARATOR): Same intervention with a 1 month delay: The full intervention will be initiated in Month 2 with a brief education session, use of Fitbit Flex, and counselling by a physiotherapist. The trial will conclude at the end of Month 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of persistent/chronic ITP for at least 3 months.~* Average platelet count \< 30,000/µL (and none \> 35,000 unless as a result of rescue therapy) from at least 3 qualifying counts~Exclusion Criteria:~* Clinical diagnosis of autoimmune hemolytic anemia~* Uncontrolled or poorly controlled hypertension~* History of coagulopathy including prothrombotic conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fostamatinib Disodium (Type: EXPERIMENTAL): Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability.
- Placebo (Type: OTHER): Placebo tablet PO bid (morning and evening) over the course of 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete